arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Structure Therapeutics Inc.

GPCR Health Care Biotechnology: Pharmaceutical Preparations
$47.34
Today
as of Sep 4, 16:49 ET
Last 30 days -1.15% Jul 28 → Sep 04
$45.21 $47.76 $50.31 $52.85 $55.40 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$47.26
High
$48.05
Low
$46.73
Volume
$253,396
Avg Vol
$1M
Mkt Cap
$3.9B
P/E (TTM)
—
Beta
—
52w High
$94.90
52w Low
$19.50
Div Yield
—
Shares Out
$214M

Recent Press Releases & News last 60 days · 3 items

Sep 3 · 11:30 PR GlobeNewswire
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Aug 26 · 12:19 Zacks
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
Aug 6 · 20:05 PR GlobeNewswire
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Overview

52-week range
$20
$95
37% of range
Avg surprise (last 3)
-10.3%
Avg reaction (last 2)
-1.7%
50% positive
Latest IV / EM
78%
EM ±12.1% · $48 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.49$-0.41$-0.33$-0.26$-0.18 Actual $-0.25Actual $-0.20Actual $-0.21Actual $-0.19Actual $-0.18Actual $-0.20Actual $-0.27Est $-0.24Actual $-0.36Est $-0.28Actual $-0.37Actual $-0.35Est $-0.39Actual $-0.49 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-106M$-89M$-71M$-53M$-36M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.49 — — — — financials
Thu May 7, 2026Mar/2026 $-0.35 $-0.39 +10.3% -29.6% -4.1% earnings
Tue Sep 30, 2025Sep 2025 $-0.37 — — — — financials
Wed Aug 6, 2025Jun/2025 $-0.36 $-0.28 -28.6% — — earnings
Thu May 8, 2025Mar/2025 $-0.27 $-0.24 -12.5% — +0.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.20 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.18 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.19 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.21 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.20 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.25 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-119M$-89M—$-74M$-70M$-56M—$-46M
Net income$-106M$-76M—$-66M$-62M$-47M—$-34M
EPS (diluted)$-0.49$-0.35—$-0.37$-0.36$-0.27—$-0.20

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$273M$316M$800M$103M$147M$152M$170M$172M
Inventory————————
Total current assets$1.37B$1.49B$1.57B$814M$799M$850M$891M$924M
Total assets$1.43B$1.51B$1.58B$832M$816M$867M$903M$933M
Long-term debt————————
Total liabilities$71M$61M$68M$62M$44M$42M$38M$36M
Total equity$1.35B$1.45B$1.52B$770M$772M$825M$865M$897M

Implied volatility — last 90 days

60%110%160%210%260% Jun 07 — IV 86% · EM ±11.9%Jun 08 — IV 88% · EM ±11.7%Jun 09 — IV 104% · EM ±13.1%Jun 10 — IV 112% · EM ±13.2%Jun 11 — IV 113% · EM ±12.5%Jun 12 — IV 94% · EM ±9.6%Jun 15 — IV 98% · EM ±7.1%Jun 16 — IV 110% · EM ±6.5%Jun 17 — IV 157% · EM ±6.6%Jun 19 — IV 61% · EM ±13.4%Jun 22 — IV 75% · EM ±15.6%Jun 23 — IV 71% · EM ±14.5%Jun 24 — IV 64% · EM ±12.8%Jun 25 — IV 69% · EM ±13.6%Jun 26 — IV 62% · EM ±11.8%Jun 29 — IV 75% · EM ±13.3%Jun 30 — IV 78% · EM ±13.4%Jul 01 — IV 64% · EM ±10.6%Jul 02 — IV 65% · EM ±10.6%Jul 03 — IV 68% · EM ±10.6%Jul 06 — IV 75% · EM ±10.4%Jul 07 — IV 76% · EM ±10.1%Jul 08 — IV 77% · EM ±9.7%Jul 09 — IV 64% · EM ±7.6%Jul 10 — IV 64% · EM ±7.1%Jul 13 — IV 92% · EM ±7.7%Jul 14 — IV 102% · EM ±7.4%Jul 15 — IV 104% · EM ±6.1%Jul 16 — IV 260% · EM ±10.9%Jul 20 — IV 86% · EM ±20.4%Jul 21 — IV 86% · EM ±20.1%Jul 22 — IV 88% · EM ±20.1%Jul 23 — IV 93% · EM ±20.9%Jul 24 — IV 85% · EM ±18.8%Jul 27 — IV 88% · EM ±18.3%Jul 28 — IV 91% · EM ±18.6%Jul 29 — IV 97% · EM ±19.5%Jul 30 — IV 85% · EM ±16.6%Jul 31 — IV 89% · EM ±17.0%Aug 03 — IV 102% · EM ±18.0%Aug 04 — IV 102% · EM ±17.6%Aug 05 — IV 100% · EM ±16.7%Aug 06 — IV 108% · EM ±17.5%Aug 07 — IV 92% · EM ±14.3%Aug 10 — IV 90% · EM ±12.5%Aug 11 — IV 95% · EM ±12.6%Aug 12 — IV 89% · EM ±11.1%Aug 13 — IV 91% · EM ±10.8%Aug 14 — IV 83% · EM ±9.2%Aug 17 — IV 117% · EM ±9.8%Aug 18 — IV 139% · EM ±10.1%Aug 19 — IV 127% · EM ±7.5%Aug 24 — IV 77% · EM ±16.0%Aug 25 — IV 75% · EM ±15.4%Aug 26 — IV 78% · EM ±15.6%Aug 27 — IV 78% · EM ±15.3%Aug 28 — IV 73% · EM ±14.0%Aug 31 — IV 77% · EM ±13.7%Sep 01 — IV 77% · EM ±13.3%Sep 02 — IV 80% · EM ±13.3%Sep 03 — IV 81% · EM ±13.0%Sep 04 — IV 78% · EM ±12.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in